Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
June 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
June 25, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with...
Kane Biotech Announces First Quarter 2024 Financial Results
May 23, 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The...
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
May 16, 2024 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
May 15, 2024 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces its intent to commercialize the patented assay...
Kane Biotech to Host Investor Webinar
April 16, 2024 09:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern...
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
April 15, 2024 09:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to...
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
April 11, 2024 09:45 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for...
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
March 26, 2024 16:05 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial...
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
March 20, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on...